130 related articles for article (PubMed ID: 10617693)
1. Sustained intracellular retention of dolastatin 10 causes its potent antimitotic activity.
Verdier-Pinard P; Kepler JA; Pettit GR; Hamel E
Mol Pharmacol; 2000 Jan; 57(1):180-7. PubMed ID: 10617693
[TBL] [Abstract][Full Text] [Related]
2. Intracellular activation and deactivation of tasidotin, an analog of dolastatin 15: correlation with cytotoxicity.
Bai R; Edler MC; Bonate PL; Copeland TD; Pettit GR; Ludueña RF; Hamel E
Mol Pharmacol; 2009 Jan; 75(1):218-26. PubMed ID: 18927208
[TBL] [Abstract][Full Text] [Related]
3. Spongistatin 1, a highly cytotoxic, sponge-derived, marine natural product that inhibits mitosis, microtubule assembly, and the binding of vinblastine to tubulin.
Bai R; Cichacz ZA; Herald CL; Pettit GR; Hamel E
Mol Pharmacol; 1993 Oct; 44(4):757-66. PubMed ID: 8232226
[TBL] [Abstract][Full Text] [Related]
4. Effects of the antimitotic natural product dolastatin 10, and related peptides, on the human malarial parasite Plasmodium falciparum.
Fennell BJ; Carolan S; Pettit GR; Bell A
J Antimicrob Chemother; 2003 Apr; 51(4):833-41. PubMed ID: 12654761
[TBL] [Abstract][Full Text] [Related]
5. The spongistatins, potently cytotoxic inhibitors of tubulin polymerization, bind in a distinct region of the vinca domain.
Bai R; Taylor GF; Cichacz ZA; Herald CL; Kepler JA; Pettit GR; Hamel E
Biochemistry; 1995 Aug; 34(30):9714-21. PubMed ID: 7626642
[TBL] [Abstract][Full Text] [Related]
6. Antitumour evaluation of dolastatins 10 and 15 and their measurement in plasma by radioimmunoassay.
Aherne GW; Hardcastle A; Valenti M; Bryant A; Rogers P; Pettit GR; Srirangam JK; Kelland LR
Cancer Chemother Pharmacol; 1996; 38(3):225-32. PubMed ID: 8646796
[TBL] [Abstract][Full Text] [Related]
7. Dolastatin 15, a potent antimitotic depsipeptide derived from Dolabella auricularia. Interaction with tubulin and effects of cellular microtubules.
Bai R; Friedman SJ; Pettit GR; Hamel E
Biochem Pharmacol; 1992 Jun; 43(12):2637-45. PubMed ID: 1632820
[TBL] [Abstract][Full Text] [Related]
8. Dolastatin 10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain.
Bai R; Pettit GR; Hamel E
Biochem Pharmacol; 1990 Jun; 39(12):1941-9. PubMed ID: 2353935
[TBL] [Abstract][Full Text] [Related]
9. Antineoplastic agents 365. Dolastatin 10 SAR probes.
Pettit GR; Srirangam JK; Barkoczy J; Williams MD; Boyd MR; Hamel E; Pettit RK; Hogan F; Bai R; Chapuis JC; McAllister SC; Schmidt JM
Anticancer Drug Des; 1998 Jun; 13(4):243-77. PubMed ID: 9627667
[TBL] [Abstract][Full Text] [Related]
10. Differential cellular retention of vincristine and vinblastine by cultured human promyelocytic leukemia HL-60/Cl cells: the basis of differential toxicity.
Ferguson PJ; Cass CE
Cancer Res; 1985 Nov; 45(11 Pt 1):5480-8. PubMed ID: 3863705
[TBL] [Abstract][Full Text] [Related]
11. Dolastatin 15 binds in the vinca domain of tubulin as demonstrated by Hummel-Dreyer chromatography.
Cruz-Monserrate Z; Mullaney JT; Harran PG; Pettit GR; Hamel E
Eur J Biochem; 2003 Sep; 270(18):3822-8. PubMed ID: 12950266
[TBL] [Abstract][Full Text] [Related]
12. Interaction of dolastatin 10 with tubulin: induction of aggregation and binding and dissociation reactions.
Bai R; Taylor GF; Schmidt JM; Williams MD; Kepler JA; Pettit GR; Hamel E
Mol Pharmacol; 1995 May; 47(5):965-76. PubMed ID: 7746283
[TBL] [Abstract][Full Text] [Related]
13. Interactions of the sponge-derived antimitotic tripeptide hemiasterlin with tubulin: comparison with dolastatin 10 and cryptophycin 1.
Bai R; Durso NA; Sackett DL; Hamel E
Biochemistry; 1999 Oct; 38(43):14302-10. PubMed ID: 10572005
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological activity of chimeric structures derived from the cytotoxic natural compounds dolastatin 10 and dolastatin 15.
Poncet J; Busquet M; Roux F; Pierré A; Atassi G; Jouin P
J Med Chem; 1998 Apr; 41(9):1524-30. PubMed ID: 9554885
[TBL] [Abstract][Full Text] [Related]
15. Preclinical pharmacology of the natural marine product dolastatin 10 (NSC 376128).
Newman RA; Fuentes A; Covey JM; Benvenuto JA
Drug Metab Dispos; 1994; 22(3):428-32. PubMed ID: 8070319
[TBL] [Abstract][Full Text] [Related]
16. Differential effects of active isomers, segments, and analogs of dolastatin 10 on ligand interactions with tubulin. Correlation with cytotoxicity.
Bai R; Roach MC; Jayaram SK; Barkoczy J; Pettit GR; Ludueña RF; Hamel E
Biochem Pharmacol; 1993 Apr; 45(7):1503-15. PubMed ID: 8471072
[TBL] [Abstract][Full Text] [Related]
17. Structure-activity studies with chiral isomers and with segments of the antimitotic marine peptide dolastatin 10.
Bai RL; Pettit GR; Hamel E
Biochem Pharmacol; 1990 Oct; 40(8):1859-64. PubMed ID: 2242019
[TBL] [Abstract][Full Text] [Related]
18. Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites.
Bai RL; Pettit GR; Hamel E
J Biol Chem; 1990 Oct; 265(28):17141-9. PubMed ID: 2211617
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the interaction of TZT-1027, a potent antitumor agent, with tubulin.
Natsume T; Watanabe J; Tamaoki S; Fujio N; Miyasaka K; Kobayashi M
Jpn J Cancer Res; 2000 Jul; 91(7):737-47. PubMed ID: 10920282
[TBL] [Abstract][Full Text] [Related]
20. Two photoaffinity analogues of the tripeptide, hemiasterlin, exclusively label alpha-tubulin.
Nunes M; Kaplan J; Wooters J; Hari M; Minnick AA; May MK; Shi C; Musto S; Beyer C; Krishnamurthy G; Qiu Y; Loganzo F; Ayral-Kaloustian S; Zask A; Greenberger LM
Biochemistry; 2005 May; 44(18):6844-57. PubMed ID: 15865430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]